BSG and neoplasm: Recently, Tian et al. reported the generation of dextran–doxorubicin prodrug nanoparticles conjugated with CD147 monoclonal antibodies, that, upon acid-sensitive disassembly in the tumor environment and endocytosis, could efficiently inhibit tumor growth [22], further reinforcing the potential of dextran in drug design.